首页> 外文OA文献 >Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype
【2h】

Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype

机译:胶质瘤中的血管生成信号通路改变:具有侵袭性表型的更具攻击性的肿瘤亚群的选择机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The angiogenesis process is a key event for glioma survival, malignancy and growth. The start of angiogenesis is mediated by a cascade of intratumoural events: alteration of the microvasculature network; a hypoxic microenvironment; adaptation of neoplastic cells and synthesis of pro-angiogenic factors. Due to a chaotic blood flow, a consequence of an aberrant microvasculature, tissue hypoxia phenomena are induced. Hypoxia inducible factor 1 is a major regulator in glioma invasiveness and angiogenesis. Clones of neoplastic cells with stem cell characteristics are selected by HIF-1. These cells, called “glioma stem cells” induce the synthesis of vascular endothelial growth factor. This factor is a pivotal mediator of angiogenesis. To elucidate the role of these angiogenic mediators during glioma growth, we have used a rat endogenous glioma model. Gliomas induced by prenatal ENU administration allowed us to study angiogenic events from early to advanced tumour stages. Events such as microvascular aberrations, hypoxia, GSC selection and VEGF synthesis may be studied in depth. Our data showed that for the treatment of gliomas, developing anti-angiogenic therapies could be aimed at GSCs, HIF-1 or VEGF. The ENU-glioma model can be considered to be a useful option to check novel designs of these treatment strategies.
机译:血管生成过程是神经胶质瘤存活,恶性肿瘤和生长的关键事件。血管生成的开始是由一系列肿瘤内事件介导的:微脉管系统网络的改变;低氧的微环境;肿瘤细胞的适应性和促血管生成因子的合成。由于微血管异常的血液流动混乱,导致组织缺氧现象。缺氧诱导因子1是神经胶质瘤侵袭和血管生成的主要调节因子。通过HIF-1选择具有干细胞特征的赘生性细胞的克隆。这些被称为“神经胶质瘤干细胞”的细胞诱导血管内皮生长因子的合成。该因子是血管生成的关键介质。为了阐明这些血管生成介质在神经胶质瘤生长过程中的作用,我们使用了大鼠内源性神经胶质瘤模型。由产前ENU给药引起的胶质瘤使我们能够研究从早期到晚期肿瘤的血管生成事件。诸如微血管畸变,缺氧,GSC选择和VEGF合成等事件可能会得到深入研究。我们的数据表明,对于神经胶质瘤的治疗,正在开发的抗血管生成疗法可能针对GSC,HIF-1或VEGF。 ENU-神经胶质瘤模型可以被认为是检查这些治疗策略的新颖设计的有用选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号